Home › Funds › EVENTIDE ASSET MANAGEMENT, LLC › MBX
EVENTIDE ASSET MANAGEMENT, LLC position in MBX
MBX BIOSCIENCES INC · Health Care
EVENTIDE ASSET MANAGEMENT, LLC reported holding 873,492 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$51.2M, representing 0.72% of its reported portfolio and ranking #42 among its reported holdings. EVENTIDE ASSET MANAGEMENT, LLC has disclosed MBX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How EVENTIDE ASSET MANAGEMENT, LLC's MBX position evolved
EVENTIDE ASSET MANAGEMENT, LLC first disclosed a stake in MBX in Q4 2025 at 890,000 shares (US$28.1M). The position peaked in Q3 2026 at 873,492 shares, worth US$51.2M. Across 4 filings, EVENTIDE ASSET MANAGEMENT, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 873,492 shares valued at US$51.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 890.00K | $28.07M | New |
| Q1 2026 | 890.00K | $26.57M | Hold |
| Q2 2026 | 873.49K | $48.22M | Reduce |
| Q3 2026 | 873.49K | $51.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC) is a Health Care company. 69 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- Paradigm Biocapital Advisors LP 2.51M sh · $138.44M · Q2 2026
- NVP Associates, LLC 2.14M sh · $125.23M · Q3 2026
- Deep Track Capital, LP 1.73M sh · $95.64M · Q2 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $51.60M · Q2 2026
- Parkman Healthcare Partners LLC 800.17K sh · $44.17M · Q2 2026
- BRAIDWELL LP 710.88K sh · $39.24M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $35.88M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
More on EVENTIDE ASSET MANAGEMENT, LLC
FAQ
How long has EVENTIDE ASSET MANAGEMENT, LLC held MBX?
EVENTIDE ASSET MANAGEMENT, LLC has disclosed MBX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is EVENTIDE ASSET MANAGEMENT, LLC's current position in MBX?
As of Q3 2026, EVENTIDE ASSET MANAGEMENT, LLC holds 873.49K shares of MBX (MBX BIOSCIENCES INC), valued at $51.20M, representing 0.72% of its reported portfolio and ranking #42.
Has EVENTIDE ASSET MANAGEMENT, LLC been buying or selling MBX?
In the latest 13F filing (Q3 2026), EVENTIDE ASSET MANAGEMENT, LLC held unchanged its position in MBX. The position peaked in Q3 2026 at 873.49K shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.